Pull to refresh
Logo
Merck KGaA buys Bio-Techne in its biggest deal since 2015

Merck KGaA buys Bio-Techne in its biggest deal since 2015

Money Moves

Germany's Merck pays $73 a share, about $11.3 billion, for a Minnesota maker of lab reagents and spatial-biology tools

June 25th, 2026: Merck KGaA agrees to buy Bio-Techne

Overview

Updated Jun 25

Merck KGaA of Darmstadt, Germany, agreed to buy Bio-Techne, a Minneapolis company that makes the reagents, proteins, and imaging tools researchers use at the lab bench. The price is $73 a share in cash, about $11.3 billion, a 36% premium over the recent trading average.

It is the German firm's largest purchase since it paid roughly $17 billion for Sigma-Aldrich in 2015. The deal hands Merck a bigger share of fast-growing niches like spatial biology and cell therapy, and tests how regulators treat a foreign buyer absorbing a US supplier of research staples.

Why it matters

Most biology labs run on a handful of suppliers; this deal puts more of those tools under one roof, shaping what scientists can buy and at what price.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$11.3B
Deal value
All-cash enterprise value Merck KGaA agreed to pay for Bio-Techne.
$73
Price per share
Cash offered for each Bio-Techne share.
36%
Premium
Markup over Bio-Techne's one-month average share price.
€140M
Annual cost synergies
Yearly savings Merck targets by the third year after closing.
2,300
Bio-Techne US staff
Roughly the number of people Bio-Techne employs in the United States.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

November 2015 June 2026

3 events Latest: June 25th, 2026 · 3 months ago
  1. Merck KGaA agrees to buy Bio-Techne

    Latest Deal

    Merck announces an all-cash agreement to acquire Bio-Techne for $73 a share, about $11.3 billion, a 36% premium. Both boards approve.

  2. Kai Beckmann takes over as CEO

    Leadership

    Beckmann becomes Merck KGaA's group chief executive, succeeding Belén Garijo, who later moves to Sanofi.

  3. Merck KGaA closes Sigma-Aldrich deal

    Deal

    Merck completes its roughly $17 billion purchase of Sigma-Aldrich, building the core of its life-science supply business.

Scenarios

1

Deal closes on schedule by early 2027

Likely Resolves by Q1 2027

Discussed by: Merck KGaA and Bio-Techne, in the joint announcement

Regulators in the US and Europe clear the purchase, and Bio-Techne shareholders vote yes. The companies have guided to a close by late 2026 or early 2027. With both boards already behind it and no obvious horizontal overlap that would alarm antitrust agencies, the base case is a clean close near that window.

2

Regulators delay the deal past mid-2027

Possible Resolves by Jul 31, 2027

Discussed by: Antitrust commentators tracking US and EU merger review of lab-tools suppliers

A foreign buyer taking over a US research-tools maker draws extended review from the US Federal Trade Commission, the European Commission, or China's market regulator. Requests for more information, or remedies such as divestitures, push the timeline well past the companies' target. The deal still survives, but later than planned.

3

Deal collapses before closing

Unlikely Resolves by Q2 2027

Discussed by: Merger-arbitrage analysts watching the spread between the offer and the trading price

The purchase falls apart. Triggers could be a regulator blocking it on competition or foreign-ownership grounds, a shareholder rejection, or a failure to meet closing conditions. This is the least likely path given board support and the cash structure, but large cross-border deals do break.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

September 2014 to November 2015

Merck KGaA buys Sigma-Aldrich (2015)

Merck KGaA agreed to buy Sigma-Aldrich, a US lab-chemicals supplier, for about $17 billion. It was the company's largest deal and the foundation of its modern life-science business.

Then

To win European approval, Merck agreed to sell parts of the combined chemicals business to Honeywell.

Now

The deal made Merck KGaA a top-tier supplier of lab reagents and consumables, the base it is now expanding with Bio-Techne.

Why this matters now

It is the direct precedent the company itself cites: the same buyer, the same strategy of acquiring US lab-supply firms, on a similar scale.

February 2019 to March 2020

Danaher acquires Cytiva from GE (2020)

Danaher paid about $21 billion for General Electric's biopharma unit, later renamed Cytiva, a major maker of bioprocessing tools used to manufacture drugs.

Then

US antitrust regulators required Danaher to divest several product lines before clearing the purchase.

Now

Cytiva became a pillar of Danaher's life-science portfolio and a benchmark for valuing lab-tools assets.

Why this matters now

It shows how rivals built scale through one large acquisition, and how antitrust agencies handle deals among a few dominant tool suppliers.

April 2021 to December 2021

Thermo Fisher buys PPD (2021)

Thermo Fisher Scientific paid about $17.4 billion for PPD, a clinical-research services firm, widening its reach across the drug-development chain.

Then

The all-cash deal closed within the year with regulatory clearance.

Now

It cemented Thermo Fisher as the largest single player in life-science tools and services.

Why this matters now

It is the kind of scale Merck KGaA is chasing, and a marker of the consolidation pulling smaller suppliers like Bio-Techne into larger parents.

Sources

(4)